The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy

Leukemia

Volumn 29, Issue 6, 2015, Pages 1320-1330

  Wang, L D ^a,b,c,d,e   Rao, T N ^a,b,c   Rowe, R G ^b,d,e,f,g   Nguyen, P T ^a,b   Sullivan, J L ^a,b   Pearson, D S ^b,d,e,f,g,h   Doulatov, S ^b,d,e,f,g   Wu, L ^i,j   Lindsley, R C ^d,k   Zhu, H ⁱ   Deangelo, D J ^d   Daley, G Q ^{b,c,d,e,f,g,h}   Wagers, A J ^a,b,c,g  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

^c Harvard University   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f Manton Center for Orphan Disease Research   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LIN28B PROTEIN; PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; LIN28B PROTEIN, HUMAN; LIN28B PROTEIN, MOUSE; MESSENGER RNA; RNA BINDING PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASOPHIL; CELL DIFFERENTIATION; CELL FATE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; MALE; MAST CELL; MOUSE; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PERITONEAL CAVITY; PERITONEUM MAST CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMIC MASTOCYTOSIS; TARGET ORGAN; UPREGULATION; ANIMAL; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL CULTURE; CYTOLOGY; FLOW CYTOMETRY; GENETICS; HEMATOPOIESIS; KNOCKOUT MOUSE; LEUKEMIA, MAST-CELL; MASTOCYTOSIS, SYSTEMIC; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELLS, CULTURED; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; HEMATOPOIESIS; HUMANS; LEUKEMIA, MAST-CELL; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MYELOID CELLS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 84930576976     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.19     Document Type: Article

References (60)

1. Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 2007; 217: 141-154.
2. Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol 2010; 40: 1843-1851.
3. De Filippo K, Dudeck A, Hasenberg M, Nye E, van Rooijen N, Hartmann K et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood 2013; 121: 4930-4937.
4. Sismanopoulos N, Delivanis DA, Mavrommati D, Hatziagelaki E, Conti P, Theoharides TC. Do mast cells link obesity and asthma? Allergy 2012; 68: 8-15.
5. Jung M, Lord MS, Cheng B, Lyons JG, Alkhouri H, Hughes JM et al. Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: A role in angiogenesis and wound healing. J Biol Chem 2013; 288: 3289-3304.
6. Younan GJ, Heit YI, Dastouri P, Kekhia H, Xing W, Gurish MF et al. Mast cells are required in the proliferation and remodeling phases of microdeformational wound therapy. Plast Reconstr Surg 2011; 128: 649e-658e.
7. Glimelius I, Edström A, Fischer M, Nilsson G, Sundström C, Molin D et al. Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia 2005; 19: 2360-2362.
8. Mizuno H, Nakayama T, Miyata Y, Saito S, Nishiwaki S, Nakao N et al. Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbedby bortezomib. Leukemia 2012; 26: 2269-2276.
9. Ribatti D, Molica S, Vacca A, Nico B, Crivellato E, Roccaro AM et al. Tryptasepositive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 2003; 17: 1428-1430.
10. Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWGMRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013; 121: 2393-2401.
11. Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013; 88: 612-624.
12. Pardanani A, Tefferi A. Systemic mastocytosis in adults: A review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 2010; 17: 125-132.
13. Nagata H, Worobec AS, Semere T, Metcalfe DD. Elevated expression of the proto-oncogene c-kit in patients with mastocytosis. Leukemia 1998; 12: 175-181.
14. Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood 2010; 116: 5812-5817.
15. Georgin-Lavialle S, Lhermitte L, Dubreuil P, Chandesris MO, Hermine O, Damaj G. Mast cell leukemia. Blood 2013; 121: 1285-1295.
16. Lasho T, Tefferi A, Pardanani A. Inhibition of JAK-STAT signaling by TG101348: A novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. Leukemia 2010; 24: 1378-1380.
17. Bubnoff von N, Gorantla SHP, Kancha RK, Lordick F, Peschel C, Duyster J. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 2005; 19: 1670-1671.
18. Chen C-C, Grimbaldeston MA, Tsai M, Weissman IL, Galli SJ. Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci USA 2005; 102: 11408-11413.
19. Arinobu Y, Iwasaki H, Gurish MF, Mizuno S-I, Shigematsu H, Ozawa H et al. Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci USA 2005; 102: 18105-18110.
20. Franco CB, Chen C-C, Drukker M, Weissman IL, Galli SJ. Distinguishing mast cell and granulocyte differentiation at the single-cell level. Cell Stem Cell 2010; 6: 361-368.
21. Salmon JM, Slater NJ, Hall MA, McCormack MP, Nutt SL, Jane SM et al. Aberrant mast-cell differentiation in mice lacking the stem-cell leukemia gene. Blood 2007; 110: 3573-3581.
22. Motakis E, Guhl S, Ishizu Y, Itoh M, Kawaji H, de Hoon M et al. Redefinition of the human mast cell transcriptome by deep-CAGE sequencing. Blood 2014; 123: e58-e67.
23. Ma P, Mali RS, Munugalavadla V, Krishnan S, Ramdas B, Sims E et al. The PI3K pathway drives the maturation of mast cells via microphthalmia transcription factor. Blood 2011; 118: 3459-3469.
24. Migliaccio AR, Rana RA, Sanchez M, Lorenzini R, Centurione L, Bianchi L et al. GATA-1 as a Regulator of Mast Cell Differentiation Revealed by the Phenotype of the GATA-1low Mouse Mutant. Journal of Experimental Medicine 2003; 197: 281-296.
25. Qi X, Hong J, Chaves L, Zhuang Y, Chen Y, Wang D et al. Antagonistic regulation by the transcription factors c/ebpa and mitf specifies basophiland mast cell fates. Immunity 2013; 39: 97-110.
26. Walsh JC, DeKoter RP, Lee HJ, Smith ED, Lancki DW, Gurish MF et al. Cooperative and antagonistic interplay between PU. 1 and GATA-2 in the specification of myeloid cell fates. Immunity 2002; 17: 665-676.
27. Shyh-Chang N, Daley GQ. Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell 2013; 12: 395-406.
28. West JA, Viswanathan SR, Yabuuchi A, Cunniff K, Takeuchi A, Park I-H et al. A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature 2009; 460: 909-913.
29. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009; 41: 843-848.
30. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
31. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-B, Lin28, Let-MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139: 693-706.
32. Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 2012; 44: 1199-1206.
33. King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee JS, Rustgi AK. LIN28B Promotes Colon Cancer Progression and Metastasis. Cancer Res 2011; 71: 4260-4268.
34. Urbach A, Yermalovich A, Zhang J, Spina CS, Zhu H, Perez-Atayde AR et al. Lin28 sustains early renal progenitors and induces Wilms tumor. Genes Dev 2014; 28: 971-982.
35. Zhu H, Shah S, Shyh-Chang N, Shinoda G, Einhorn WS, Viswanathan SR et al. Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet 2010; 42: 626-630.
36. Zhu H, Shyh-Chang N, Segrè AV, Shinoda G, Shah SP, Einhorn WS et al. The Lin28/ let-7 axis regulates glucose metabolism. Cell, Elsevier Inc; 2011; 147: 81-94.
37. Shyh-Chang N, Zhu H, de Soysa TY, Shinoda G, Seligson MT, Tsanov KM et al. Lin28 enhances tissue repairby reprogramming cellular metabolism. Cell 2013; 155: 778-792.
38. Wilbert ML, Huelga SC, Kapeli K, Stark TJ, Liang TY, Chen SX et al. LIN28 binds messenger RNAs at GGAGA motifs and regulates splicing factor abundance. Mol Cell 2012; 48: 195-206.
39. Cho J, Chang H, Kwon SC, Kim B, Kim Y, Choe J et al. LIN28A is a suppressor of ER-associated translation in embryonic stem cells. Cell 2012; 151: 765-777.
40. Yuan J, Nguyen CK, Liu X, Kanellopoulou C, Muljo SA. Lin28b reprograms adult bone marrow hematopoietic progenitors to mediate fetal-like lymphopoiesis. Science 2012; 335: 1195-1200.
41. Lee YT, de Vasconcellos JF, Yuan J, Byrnes C, Noh SJ, Meier ER et al. LIN28Bmediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo. Blood 2013; 122: 1034-1041.
42. Copley MR, Babovic S, Benz C, DJHF Knapp, Beer PA, Kent DG et al. The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells. Nat Cell Biol 2013; 15: 916-925.
43. Chaudhuri AA, So AYL, Mehta A, Minisandram A, Sinha N, Jonsson VD et al. Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. Proc Natl Acad Sci USA 2012; 109: 4233-4238.
44. Beachy SH, Onozawa M, Chung YJ, Slape C, Bilke S, Francis P et al. Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma. Blood 2012; 120: 1048-1059.
45. Rao S, Lee SY, Gutierrez A, Perrigoue J, Thapa RJ, Tu Z et al. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood 2012; 120: 3764-3773.
46. Yuan J, Muljo SA. Exploring the RNA world in hematopoietic cells through the lens of RNA-binding proteins. Immunol Rev 2013; 253: 290-303.
47. Mican JA, Arora N, Burd PR, Metcalfe DD. Passive cutaneous anaphylaxis in mouse skin is associated with local accumulation of interleukin-6 mRNA and immunoreactive interleukin-6 protein. J Allergy Clin Immunol 1992; 90: 815-824.
48. Arock M, Le Nours A, Malbec O, Daëron M. Ex vivo and in vitro primary mast cells. Methods Mol Biol 2008; 415: 241-254.
49. Hallgren J, Gurish MF. Mast cell progenitor trafficking and maturation. Adv Exp Med Biol 2011; 716: 14-28.
50. Jamur MC, Moreno AN, Mello LF, Souza Júnior DA, Campos MRC, Pastor MVD et al. Mast cell repopulation of the peritoneal cavity: contribution of mast cell progenitors versus bone marrow derived committed mast cell precursors. BMC Immunol 2010; 11: 32.
51. Ekoff M, Nilsson G. Mast cell apoptosis and survival. Adv Exp Med Biol 2011; 716: 47-60.
52. Fukuishi N, Igawa Y, Kunimi T, Hamano H, Toyota M, Takahashi H et al. Generation of mast cells from mouse fetus: analysis of differentiation and functionality, and transcriptome profiling using next generation sequencer. PLoS ONE 2013; 8: e60837.
53. Dvorak AM. Ultrastructural studies of human basophils and mast cells. J Histochem Cytochem 2005; 53: 1043-1070.
54. Tenen DG. Abnormalities of the CEBP alpha transcription factor: A major target in acute myeloid leukemia. Leukemia 2001; 15: 688-689.
55. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG. CCAAT/ enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998; 18: 4301-4314.
56. Iwasaki H, Mizuno S-I, Wells RA, Cantor AB, Watanabe S, Akashi K. GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages. Immunity 2003; 19: 451-462.
57. Sánchez-Muñoz L, Teodósio C, Morgado JM, Escribano L. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Methods Cell Biol 2011; 103: 333-359.
58. Verstovsek S. Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol 2013; 90: 89-98.
59. Gotlib J, DeAngelo DJ, George TI, Corless CL, Linder A, Langford C et al. KIT inhibitor midostaurin exhibits a high rate of clincally meaningful and durable responses in advanced systemic mastocytosis: report of a full accrued phase II trial. Blood 2010; 116: 316.
60. Elliott MA, Pardanani A, Li CY, Tefferi A. Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis. Leukemia 2004; 18: 1027-1029.